Objective To observe the safety and efficacy of nafamostat mesylate for anticoagulation in maintenance hemodialysis patients. Methods Patients on hemodialysis were randomly divided into two groups, nafamostat mesylate for injection group and sodium heparin injection group, respectively. The safety and efficacy of nafamostat were evaluated.Results The anticoagulation efficiency of nafamostat mesylate for injection group and sodium heparin injection group was 97.2% and 98.2%, respectively (χ2=0.000，P=0.992); The effect of nafamostat mesylate for injection group on activated clotting time (ACT) during dialysis was less than that of sodium heparin injection group.The ACT values at the arterial side of the two groups were significantly different (1h, t=-15.333, P＜0.001; 2h, Z=-10.317, P＜0.001; 3h,t=-12.733, P＜0.001; the end of dialysis, Z=-6.796, P＜0.001),the venous side of the two groups were significant statistical differences in ACT values(1h, t=-17.833, P<0.001; 2h, t=-15.604, P＜0.001; 3h, Z=-10.066, P＜0.001; the end of dialysis,Z=-4.399, P＜0.001);After the end of hemodialysis, the nafamostat mesylate group for injection had less effect on activated partial thromboplastin time (Z=-4.971, P＜0.001) and thrombin time (Z =5.770, P＜0.001) than the heparin sodium injection group ; The incidence of adverse reactions in nafamostat mesylate for injection group was lower than heparin sodium injection group (χ2=15.239，P＜0.001). Conclusion The anticoagulant effect of nafamostat mesylate is non-inferior to sodium heparin , and the incidence of adverse reactions is lower.It could be used safely and effectively in the anticoagulation of hemodialysis.
ZHUANG Bing
,
YE Hong
,
CAO Hong-Di
,
BIAN Xue-Qin
,
ZHONG Hua
,
LUO Yuan
,
PENG Kan-Fu
,
SHI Hui
,
YANG Jun-Wei
. A multicenter randomized controlled study of nafamostat mesylate for anticoagulation therapy on hemodialysis[J]. Chinese Journal of Blood Purification, 2022
, 21(10)
: 739
-743
.
DOI: 10.3969/j.issn.1671-4091.2022.10.008
[1]Claudel SE, Miles LA, Murea M.Anticoagulation in hemodialysis: A narrative review. [J].Semin Dial., 2021, 34(2):103-115
[2]Nadarajah L, Fan S, Forbes S, et al.Major bleeding in hemodialysis patients using unfractionated or low molecular weight heparin: a single-center study. [J].Clin Nephrol. , 2015, 84(5):274-279
[3]Oh HS, Kim T, Gu DH, et al.Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis. [J].Molecules. , 2022, 27(6):1881-1894
[4]Arimura T, Abe M, Shiga H, et al.Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013. [J].J Artif Organs. , 2017, 20(3):244-251
[5]Inokuchi R, Kuno T, Komiyama J, et al.Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study. [J].J Clin Med. , 2021, 11(1):116-125
[6]Takada N, Sugano H, Shirai Y, et al.Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells.[J]. PLoS One., 2021, 16(9):e0257019-e0257034
[7]Naumnik B,My?liwiec M..Dialysis: Heparin-free haemodialysis--use and outcomes. [J].Nat Rev Nephrol. , 2013, 9(7):381-382
[8]唐小琰, 张凌, 付平.局部枸橼酸抗凝在间歇性血液透析中的应用进展[J].中国血液净化, 2021, 20(06):387-390
[9]杨松涛, 赵娜, 胡军, 等.应用普通含钙透析液局部枸橼酸抗凝血液透析的临床观察[J].中国血液净化, 2017, 16(07):474-476
[10]Yu G, Li S, Wan R, et al.Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials. [J].Pancreas, 2015, 44(4):561-569
[11]Amanzadeh J, Reilly RF Jr.Anticoagulation and continuous renal replacement therapy.[J].Semin Dial., 2006, 19(4):311-316
[12]Takahashi W, Yoneda T, Koba H, et al.Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. [J]. Int J Infect Dis, 2021, 102(/):529-531
[13]Ianevski A, Yao R, Lysvand H, et al.Nafamostat-Interferon-αCombination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2.[J].Viruses, 2021, 13(9):1768-1776
[14]Maruyama Y, Yoshida H, Uchino S, et al.Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis:a three-year retrospective cohort study.[J]. Int J Artif Organs., 2011, 34(7):571-576
[15]北村伸哉, 张凌.甲磺酸萘莫司他在连续性肾脏替代治疗中的抗凝应用[J].华西医学, 2018, 33(7):801-805
[16]Inoue Y, Tsychihashi Y, Ohsaka M, et al.Optimal target of ACT for an appropriate nafamostat mesilate dosage during continuous renal replacement therapy.[J].J Jpn Soc Blood Purif Crit Care, 2010, 102(1):124-130
[17]Miyatake Y, Makino S, Kubota K, et al.Association between intracircuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate:a retrospective pilot observational study[J].Kobe J Med Sci, 2017, 63(1):E30-E36
[18]Maruyama H, Miyakawa Y, Gejyo F, et al.Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient[J].Nephron, 1996, 74(2):468-469
[19]Yamazato M, Mano R, Oshiro-Chinen S, et al.Severe abdominal pain associated with allergic reaction to nafamostat mesilate in chronic hemodialysis patient[J].Intern Med, 2002, 41(10):864-866
[20]Kim JH, Park JY, Jang SH, et al.Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis. [J].Allergy Asthma Immunol Res. , 2021, 13(3):517-519
